The role of stakeholder involvement in the evolving EU HTA process:

EUHTA Health policy Health technology assessment Stakeholder involvement

Journal

Journal of market access & health policy
ISSN: 2001-6689
Titre abrégé: J Mark Access Health Policy
Pays: United States
ID NLM: 101670174

Informations de publication

Date de publication:
2023
Historique:
medline: 7 6 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: epublish

Résumé

Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA framework to assess their current level of involvement, determine their suggested future role, identify challenges to contribution, and highlight efficient ways to fulfilling their role. The 'key' stakeholder groups identified and covered by this research included: patients', clinicians', regulatory, and Health Technology Developer representatives. The survey was circulated to a wide expert audience including all relevant stakeholder groups in order to determine self-perception by the 'key' stakeholders regarding involvement in the HTA process (self-rating), and in a second, slightly modified version of the questionnaire, to determine the perception of 'key' stakeholder involvement by HTA bodies, payers, and policymakers (external rating). Predefined analyses were conducted on the submitted responses. Fifty-four responses were received (patients 9; clinicians: 8; regulators: 4; HTDs 14; HTA bodies: 7; Payers: 5; policymakers 3; others 4). The mean self-perceived involvement score was consistently lower for each of the 'key' stakeholder groups than the respective external ratings. Based on the qualitative insights generated in the survey, a RACI Chart (Responsible/Accountable/Consulted/Informed) was developed for each of the stakeholder groups to determine their roles and involvement in the current EU HTA process. Our findings suggest extensive effort and a distinct research agenda are required to ensure adequate involvement of the key stakeholder groups in the evolving EU HTA process.

Identifiants

pubmed: 37284060
doi: 10.1080/20016689.2023.2217543
pii: 2217543
pmc: PMC10240997
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2217543

Informations de copyright

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Déclaration de conflit d'intérêts

The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

Références

Int J Technol Assess Health Care. 2009 Dec;25 Suppl 2:84-91
pubmed: 20030895
Qual Health Res. 2021 Jul;31(8):1555-1564
pubmed: 33980102
Health Econ Rev. 2022 Jun 2;12(1):30
pubmed: 35652987
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):251-261
pubmed: 30696372
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Sep;62(9):1113-1119
pubmed: 31420717
Front Public Health. 2020 Sep 22;8:457
pubmed: 33072683
Eur J Cancer. 2022 May;166:145-164
pubmed: 35290915
Qual Life Res. 2022 Jan;31(1):303-315
pubmed: 34129172
Health Econ Rev. 2022 Nov 5;12(1):54
pubmed: 36333433

Auteurs

Lauren Van Haesendonck (L)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Jörg Ruof (J)

r-connect Ltd, Basel, Switzerland.
Medical School of Hanover, Hanover, Germany.

Thomas Desmet (T)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Healthcare Management Centre, Vlerick Business School, Brussels, Belgium.

Walter Van Dyck (W)

Healthcare Management Centre, Vlerick Business School, Brussels, Belgium.

Steven Simoens (S)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Isabelle Huys (I)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Rosa Giuliani (R)

Guy's and St Thomas' NHS Foundation Trust, London, UK.

Mondher Toumi (M)

Faculty of Medicine, Public Health Department, Aix-Marseille University, Marseille, France.

Christian Dierks (C)

Dierks+Company, Berlin, Germany.

Juliana Dierks (J)

Dierks+Company, Berlin, Germany.

Antonella Cardone (A)

Cancer Patients Europe Brussels, Belgium.

Francois Houÿez (F)

European Organisation for Rare Diseases (EURORDIS), Paris, France.

Mira Pavlovic (M)

Medicines Development and Training (MDT) Services, Paris, France.

Michael Berntgen (M)

Scientific Evidence Generation department, European Medicines Agency (EMA), Amsterdam, The Netherlands.

Peter G M Mol (PGM)

Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.

Anja Schiel (A)

Norwegian Medicines Agency (NOMA), Oslo, Norway.

Wim Goettsch (W)

National Health Care Institute, Diemen, The Netherlands.

Fabrizio Gianfrate (F)

University of Ferrara, Ferrara, Italy.
School of Economics and Management, Cattaneo-LIUC University, Castellanza, Italy.

Stefano Capri (S)

Health Economics and Payer Evidence, Astra Zeneca, Cambridge, UK.

James Ryan (J)

Global Market Access & Pricing, Abbvie AG, Cham, Switzerland.

Pierre Ducournau (P)

HiTT Foundation, International University of Catalonia-UIC, Barcelona, Spain.

Oriol Solà-Morales (O)

Utrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, The Netherlands.

Elaine Julian (E)

r-connect Ltd, Basel, Switzerland.

Classifications MeSH